A multi-biomarker disease activity score for monitoring rheumatoid arthritis

References

• Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316–1322.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol. 2014;24(1):33–40.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Rheumatoid arthritis. Available from: http://www.cdc.gov/arthritis/basics.rheumatoid.htm. Accessed February 9, 2015.
   Google Scholar
• Fransen J, Moens HB, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis. 2005;64(9):1294–1298.
   Web of Science ®Google Scholar
• Svensson B, Schaufelberger C, Teleman A, Theander J. Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Farmacotherapy. Rheumatology (Oxford). 2000;39(9):1031–1036.
   Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JW, et al; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–637.
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263–269.
   PubMed Web of Science ®Google Scholar
• Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66(11):1443–1449.
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum. 2005;58(Suppl 2):S126–S135.
   Google Scholar
• Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012; 64(5):640–647.
   PubMed Web of Science ®Google Scholar
• Singh JA, Furst DE, Bhart A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease- modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–639.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.
   PubMed Web of Science ®Google Scholar
• Felson DT, Smolen JS, Wells G, et al; European League Against Rheumatism. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573–586.
   PubMed Web of Science ®Google Scholar
• Gibson DS, Finnegan S, Pennington S, et al. Validation of protein biomarkers to advance the management of autoimmune disorders. In: Huang FP, editor. Current Concepts and Advances from Bedside to Mechanistic Insights. Rijeka, Croatia/Shanghai, China: In Tech; 2011. Available at: http://cdn.intechweb.org/pdfs/20666.pdf. Accessed February 9, 2015.
   Google Scholar
• Liao H, Wu J, Kuhn E, et al. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum. 2004;50(12):3792–3803.
   PubMed Web of Science ®Google Scholar
• Kay J, Morgacheva O, Messing SP, et al. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther. 2014;16:R40.
   PubMed Web of Science ®Google Scholar
• Willemze A, Toes RE, Huizinga TW, et al. New biomarkers in rheumatoid arthritis. Neth J Med. 2012;70(9):392–399.
   PubMed Web of Science ®Google Scholar
• Chandrashekara S. Current studies of biomarkers for the early diagnosis of rheumatoid arthritis. Curr Biomark Find. 2014;4:107–119.
   Google Scholar
• Centola M, Cavet G, Shen Y, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One. 2013;8(4):e60635.
   PubMed Web of Science ®Google Scholar
• Curtis JR, van der Helm-van Mil AH, Knevel R, et al. validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2012;64(12):1794–1803.
   PubMed Web of Science ®Google Scholar
• Bakker MF, Cavet G, Jacobs JW, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis. 2012;71(10):1692–1697.
   PubMed Web of Science ®Google Scholar
• Eastman PS, Manning WC, Qureshi F, et al. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal. 2012;70:415–424.
   PubMed Web of Science ®Google Scholar
• Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 2007;66(3):407–409.
   PubMed Web of Science ®Google Scholar
• Hirata S, Dirven L, Shen Y, et al. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford). 2013(7);52:1202–1207.
   Google Scholar
• Van der Helm-van Mil AH, Knevel R, Cavet G, Huizinga TW, Haney DJ. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology (Oxford). 2013;52(5):839–846.
   PubMed Web of Science ®Google Scholar
• Burmester G, Weinblatt M, McInnes I, et al; EARTH Study Group. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis. 2013;72(9):1445–1452.
   PubMed Web of Science ®Google Scholar
• Hirata S, Li W, Defranoux N, et al. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. Mod Rheumatol. 2015;25(3):344–349.
   PubMed Web of Science ®Google Scholar
• Iannaccone CK, Lee YC, Cui J, et al. Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study. Rheumatology (Oxford). 2011;50(1):40–46.
   Web of Science ®Google Scholar
• Markusse IM, Dirven L, van den Broek M, et al. A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study. J Rheumatol. 2014;41(11):2114–2119.
   PubMed Web of Science ®Google Scholar
• Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis. 2015; 74(6):1102–1109.
   PubMed Web of Science ®Google Scholar
• Peabody JW, Strand V, Shimkhada R, Lee R, Chernoff D. Impact of Rheumatoid Arthritis Disease Activity Test on Clinical Practice. PLoS One. 2013;(8)5:e63215.
   Web of Science ®Google Scholar
• Li W, Sasso EH, Emerling D, Cavet G, Ford K. Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. Curr Med Res Opin. 2013;29(1):85–92.
   PubMed Web of Science ®Google Scholar
• Segurado OG, Sasso EH. Vectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2014;32 Suppl 85(5):S29–S34.
   Google Scholar
• Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369(5):448–457.
   PubMed Web of Science ®Google Scholar